The planned study aims at profiling the circadian clock, via characterizing the expression of circadian clock genes (BMAL1 and PER2) in healthy children, and children suffering from ALL and AML, and to correlate it with the age group, the presence of leukaemia and the administration of anti-leukaemia therapy. The gene discussed is BMAL1; the disease is acute myeloid leukemia.